Abstract: There are more than 15% couples suffer from infertility within 1 year. One in eight couples encounters problems when attempting to conceive a first child and one in six when attempting to conceive a subsequent child. The causes of infertility both of male and female could share
type 5 (PDE5) inhibitor has been established as first line treatment of erectile dysfunction and shift new paradigm of diagnosis and treatment of erectile dysfunction. The big success of sildenafil in pharmaceutical R&D induced the consecutive development of the so-called 'The second Viagra', e.g., tadalafil and vardenafil in 2003. Currently, these 3 kinds of PDE5 inhibitors are most famous and well-known PDE5 inhibitors worldwide. From the early competition, PDE5 inhibitors have been continuously evolved through completion for survival. In Korea, another 3 kinds of PDE5 inhibitors, udenafil [2005] , mirodenafil [2007] and avanafil [2011] have been developed. Additionally 60 generic sildenafils from 49 companies were released with termination of sildenafil patent in Korea, 2012 and 160 generic tadalafils from 64 companies were released with termination of tadalafil patent in Korea, 2015. Besides of Korea PDE5I, generic sildenafil and generic tadalafil induce cheaper PDE5I, as much as 1/5 of original PDE5Is. The dosage concept also evolved from on-demand to daily low-dose and alternative dosage. These changes of dosage concept was proved from safety of daily use and indication of PDE5Is for ED also evolved beyond ED and widened to pulmonary hypertension of Sildenafil, benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) of tadalafil and penile rehabilitation after RRP. For the launching of Generic PDE5Is, the preparation also evolved from tablet to orodisposable film, granule and chewable. The orodisposable film and chewable is favorable from patients. In Korea, the impact of recent generic tadalafil is totally different from those of generic Sildenafil in 2012. The long half-life of tadalafil enabled the approval for BPH/ LUTS with daily low dose usage. In turn, the generic Cialis also will be developed as various preparations including orodisposable film and as combination with antihypertensive for ED/HT, PDE5 inhibitor with alpha blockers for ED/ LUTS and PDE5 inhibitor with antidepressant for ED/PE. Since the launching of sildenafil citrate in 1998, the PDE5 inhibitors have been evolved into various drugs including generics, change of dosage concept, widened indication beyond ED and various preparations. From now, various forms of combination drugs will be emerged for cross risk factor treatment, reduction of pill burden and price, and eventual ED prevention and cure. Abstract: There are more than 15% couples suffer from infertility within 1 year. One in eight couples encounters problems when attempting to conceive a first child and one in six when attempting to conceive a subsequent child. The causes of infertility both of male and female could share 50%. With the recent advances in assisted fertilization such as in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), the couples suffer from infertility would like to choose assisted fertilization and nearly 1 million cycles ICSI were carried out in China every year, even its pregnancy rate 40% and live birth rate 35%, with very costed and with risks of inherent and born defects. Among of male factors of infertility, varicoceles are highly relevant (38%) and can result in a myriad of deleterious effects on male reproduction. Varicocele repair may be effective in men with subnormal semen analysis, a clinical varicocele and otherwise unexplained infertility. Numerous therapeutic options are available for correcting varicoceles, including surgical varicocelectomy and radiographic venous embolization. However, recent studies demonstrated that microsurgery for varicocele correction, with the lowest recurrence rate and the highest pregnancy rate compared with other surgical approaches, is a more cost-effective therapeutic modality than both assisted fertility for in infertility couples and it is safe and effective compared to the others surgical approaches. Obstructive azoospermia (OA) are highly prevalent (13%) in male infertility results from obstruction of the excurrent ducts (due to many causes) at any location between the rete testis and the ejaculatory ducts. Recent advances in microsurgical approaches with reversal rate 63.8-79.2%, pregnancy rate 30.6-35.8%. According to the calculations of cost per delivery for vasectomy reversal vs. sperm retrieval/ICSI, under a wide variety of initial assumptions, it is clear that vasectomy reversal/epididymovasostomy is associated with a considerably lower cost per delivery and higher delivery rates. Sperm retrieval and ICSI must yield an 81% pregnancy rate per cycle to achieve equal costs to vasectomy reversal. For the treatment of non-obstructive azoospermia (NOA), microdissection TESE is a more effective approach than other TESE approaches for ICSI, with a patency rate 40-60%, which change the impossible to possible for NOA patients, who want their own inherent child. In our center, there are more than 4,000 cases of patients were treated by microsurgery, including microsurgical varicocelectomy/ vasectomy reversal/epididymovasostomy/microdissection TESE, from 2006 to 2016. We think that microsurgical training is important for urologists and clinical. Up to now, in the recent decade, we have trained about 500 surgeons for microsurgery from 30 provinces in China. In summary, the excellent efficacies were noted by microsurgical approaches for male infertility on varicoceles and OA, with lower cost and risks of inherent and born defects compared to in assisted fertilization such as IVF and ICSI. 
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Background: As a novel therapeutic method for erectile dysfunction (ED), the Low Energy Shock Wave (LESW) has been applied in the clinical setting recently. We feel that a summary of the current literature and a systematic review to evaluate the therapeutic efficacy of LESW for ED would be helpful for physicians who are interested in using this modality to treat patients. Methods: A comprehensive search of the PubMed and EMBASE databases to November 2015 was performed. Studies reporting on patients with ED treated by LESW were included. The international index of erectile function (IIEF) score and Erection Hardness Score (EHS) were the most commonly used tools to evaluate the therapeutic efficacy of LESW. Results: There were 14 studies including 806 patients from 2005 to 2015. Seven of the 14 studies were randomized controlled trials (RCTs). In these studies, the setup parameters of LESW and the protocols of treatment were in variation. The meta-analysis revealed that LESW could improve IIEF score (MD =2.00; 95% CI, 0.99-3.00; P<0.0001) and EHS score (RD =0.16; 95% CI, 0.03-0.28; P=0.01) significantly. The therapeutic efficacy could last at least three months. The patients with mild-moderate ED
